Literature DB >> 20583086

The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.

Austin L Spitzer1, Oliver B Lao, André A S Dick, Ramasamy Bakthavatsalam, Jeffrey B Halldorson, Matthew M Yeh, Melissa P Upton, Jorge D Reyes, James D Perkins.   

Abstract

To expand the donor liver pool, ways are sought to better define the limits of marginally transplantable organs. The Donor Risk Index (DRI) lists 7 donor characteristics, together with cold ischemia time and location of the donor, as risk factors for graft failure. We hypothesized that donor hepatic steatosis is an additional independent risk factor. We analyzed the Scientific Registry of Transplant Recipients for all adult liver transplants performed from October 1, 2003, through February 6, 2008, with grafts from deceased donors to identify donor characteristics and procurement logistics parameters predictive of decreased graft survival. A proportional hazard model of donor variables, including percent steatosis from higher-risk donors, was created with graft survival as the primary outcome. Of 21,777 transplants, 5051 donors had percent macrovesicular steatosis recorded on donor liver biopsy. Compared to the 16,726 donors with no recorded liver biopsy, the donors with biopsied livers had a higher DRI, were older and more obese, and a higher percentage died from anoxia or stroke than from head trauma. The donors whose livers were biopsied became our study group. Factors most strongly associated with graft failure at 1 year after transplantation with livers from this high-risk donor group were donor age, donor liver macrovesicular steatosis, cold ischemia time, and donation after cardiac death status. In conclusion, in a high-risk donor group, macrovesicular steatosis is an independent risk factor for graft survival, along with other factors of the DRI including donor age, donor race, donation after cardiac death status, and cold ischemia time.

Entities:  

Mesh:

Year:  2010        PMID: 20583086     DOI: 10.1002/lt.22085

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  95 in total

1.  Resolution of donor non-alcoholic fatty liver disease following liver transplantation.

Authors:  Andrew D Posner; Samuel T Sultan; Norann A Zaghloul; William S Twaddell; David A Bruno; Steven I Hanish; William R Hutson; Laci Hebert; Rolf N Barth; John C LaMattina
Journal:  Clin Transplant       Date:  2017-07-13       Impact factor: 2.863

2.  An ultrasonic caliper device for measuring acoustic nonlinearity.

Authors:  Christopher Hunter; Oleg A Sapozhnikov; Adam D Maxwell; Vera A Khokhlova; Yak-Nam Wang; Brian MacConaghy; Wayne Kreider
Journal:  Phys Procedia       Date:  2016

Review 3.  Transplant for the very sick: No limitations in donor quality?

Authors:  Jennifer C Lai
Journal:  Liver Transpl       Date:  2017-10       Impact factor: 5.799

Review 4.  [Living liver donor: indications and technical aspects].

Authors:  S Nadalin; I Capobianco; I Königsrainer; B Harder; A Königsrainer
Journal:  Chirurg       Date:  2015-06       Impact factor: 0.955

5.  Susceptibility of Rat Steatotic Liver to Ischemia-Reperfusion Is Treatable With Liver-Selective Matrix Metalloproteinase Inhibition.

Authors:  Xiangdong Wang; Christopher J Walkey; Ana C Maretti-Mira; Lei Wang; Deborah L Johnson; Laurie D DeLeve
Journal:  Hepatology       Date:  2020-10-22       Impact factor: 17.425

Review 6.  Donor Hepatic Steatosis and Outcome After Liver Transplantation: a Systematic Review.

Authors:  Michael J J Chu; Anna J Dare; Anthony R J Phillips; Adam S J R Bartlett
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

7.  [High donor age for liver transplantation : Tackling organ scarcity in Germany].

Authors:  S Moosburner; P V Ritschl; L Wiering; J M G V Gassner; R Öllinger; J Pratschke; I M Sauer; N Raschzok
Journal:  Chirurg       Date:  2019-09       Impact factor: 0.955

8.  Elevated sensitivity of macrosteatotic hepatocytes to hypoxia/reoxygenation stress is reversed by a novel defatting protocol.

Authors:  Nir I Nativ; Gabriel Yarmush; Ashley So; Jeffery Barminko; Timothy J Maguire; Rene Schloss; Francois Berthiaume; Martin L Yarmush
Journal:  Liver Transpl       Date:  2014-07-02       Impact factor: 5.799

9.  Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.

Authors:  Ricardo C Gehrau; Valeria R Mas; Catherine I Dumur; Jihee L Suh; Ashish K Sharma; Helen P Cathro; Daniel G Maluf
Journal:  Transplantation       Date:  2015-12       Impact factor: 4.939

10.  Evaluation of hepatic steatosis in dogs with congenital portosystemic shunts using Oil Red O staining.

Authors:  G B Hunt; J A Luff; L Daniel; R Van den Bergh
Journal:  Vet Pathol       Date:  2013-03-25       Impact factor: 2.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.